Skip to main content

Advertisement

SpringerLink
Log in

A multicenter phase I trial of combination therapy with interferon-β and temozolomide for high-grade gliomas (INTEGRA study): the final report

  • Clinical Study – Patient Study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Our previous study demonstrated that interferon-β markedly enhanced chemosensitivity to temozolomide; one of the major mechanisms is downregulation of O6-methylguanine DNA-methyltransferase transcription via p53 induction. This effect was also observed in an experimental animal model. The results of these studies suggest that compared to temozolomide-based chemotherapy performed concomitantly with radiotherapy, chemotherapy with interferon-β and temozolomide and concomitant radiotherapy might further improve the clinical outcomes of patients with malignant gliomas. A multicenter phase I clinical trial—the Integrated Japanese Multicenter Clinical Trial: a Phase I Study of Interferon-β and Temozolomide for Glioma in Combination with Radiotherapy (INTEGRA Study)—was conducted in patients with high-grade gliomas in order to evaluate the safety, feasibility, and preliminary clinical effectiveness of combination therapy with interferon-β and temozolomide. The primary endpoint was the incidence of adverse events. The exploratory endpoints were progression-free survival time and overall survival time. The study population comprised 16 patients with newly diagnosed and 7 patients with recurrent high-grade gliomas. Grades 3–4 leukocytopenia and neutropenia were observed in 6.7 and 13.3% of patients, respectively. Overall, 40% of patients showed an objective response to therapy. In patients with newly diagnosed glioblastoma, the median overall survival time was 17.1 months and the rate of 1-year progression-free survival was 50%. We conclude that this regimen is safe and well tolerated and may prolong survival of patients with glioblastoma. A phase II clinical study is essential to corroborate our findings.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97–109

    Article  PubMed  Google Scholar 

  2. Nagane M, Levitzki A, Gazit A, Cavenee WK, Huang HJ (1998) Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. Proc Natl Acad Sci USA 95:5724–5729

    Article  PubMed  CAS  Google Scholar 

  3. Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL, Burkhard C, Schuler D, Probst-Hensch NM, Maiorka PC, Baeza N, Pisani P, Yonekawa Y, Yasargil MG, Lutolf UM, Kleihues P (2004) Genetic pathways to glioblastoma: a population-based study. Cancer Res 64:6892–6899

    Article  PubMed  CAS  Google Scholar 

  4. Ohgaki H, Kleihues P (2005) Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 64:479–489

    PubMed  CAS  Google Scholar 

  5. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996

    Article  PubMed  CAS  Google Scholar 

  6. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003

    Article  PubMed  CAS  Google Scholar 

  7. Chawla-Sarkar M, Lindner DJ, Liu YF, Williams BR, Sen GC, Silverman RH, Borden EC (2003) Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 8:237–249

    Article  PubMed  CAS  Google Scholar 

  8. Wakabayashi T, Hatano N, Kajita Y, Yoshida T, Mizuno M, Taniguchi K, Ohno T, Nagasaka T, Yoshida J (2000) Initial and maintenance combination treatment with interferon-beta, MCNU (Ranimustine), and radiotherapy for patients with previously untreated malignant glioma. J Neurooncol 49:57–62

    Article  PubMed  CAS  Google Scholar 

  9. Natsume A, Ishii D, Wakabayashi T, Tsuno T, Hatano H, Mizuno M, Yoshida J (2005) IFN-beta down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide. Cancer Res 65:7573–7579

    PubMed  CAS  Google Scholar 

  10. Natsume A, Wakabayashi T, Ishii D, Maruta H, Fujii M, Shimato S, Ito M, Yoshida J (2008) A combination of IFN-beta and temozolomide in human glioma xenograft models: implication of p53-mediated MGMT downregulation. Cancer Chemother Pharmacol 61:653–659

    Article  PubMed  CAS  Google Scholar 

  11. Aoki T, Takahashi JA, Ueba T, Oya N, Hiraoka M, Matsui K, Fukui T, Nakashima Y, Ishikawa M, Hashimoto N (2006) Phase II study of nimustine, carboplatin, vincristine, and interferon-beta with radiotherapy for glioblastoma multiforme: experience of the Kyoto Neuro-Oncology Group. J Neurosurg 105:385–391

    Article  PubMed  CAS  Google Scholar 

  12. Hatano N, Wakabayashi T, Kajita Y, Mizuno M, Ohno T, Nakayashiki N, Takemura A, Yoshida J (2000) Efficacy of post operative adjuvant therapy with human interferon beta, MCNU and radiation (IMR) for malignant glioma: comparison among three protocols. Acta neurochirurgica 142:633–638; discussion 639

    Article  PubMed  CAS  Google Scholar 

  13. Watanabe T, Katayama Y, Yoshino A, Fukaya C, Yamamoto T (2005) Human interferon beta, nimustine hydrochloride, and radiation therapy in the treatment of newly diagnosed malignant astrocytomas. J Neurooncol 72:57–62

    Article  PubMed  CAS  Google Scholar 

  14. Yoshida J, Kajita Y, Wakabayashi T, Sugita K (1994) Long-term follow-up results of 175 patients with malignant glioma: importance of radical tumour resection and postoperative adjuvant therapy with interferon, ACNU and radiation. Acta Neurochir 127:55–59

    Article  CAS  Google Scholar 

  15. Wakabayashi T, Kayama T, Nishikawa R, Takahashi H, Yoshimine T, Hashimoto N, Aoki T, Kurisu K, Natsume A, Ogura M, Yoshida J (2008) A multicenter phase I trial of interferon-beta and temozolomide combination therapy for high-grade gliomas (INTEGRA Study). Jpn J Clin Oncol 38:715–718

    Article  PubMed  Google Scholar 

  16. Motomura K, Natsume A, Kishida Y, Higashi H, Kondo Y, Nakasu Y, Abe T, Namba H, Wakai K, Wakabayashi T (2010) Benefits of interferon-beta and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: a multicenter study. Cancer. doi:10.1002/cncr.25637

Download references

Acknowledgment

This work was supported by grants from the Japan Brain Foundation (A.N.).

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Nagoya University School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan

    Toshihiko Wakabayashi, Masatoshi Ogura, Atsushi Natsume & Jun Yoshida

  2. Department of Neurosurgery, Yamagata University School of Medicine, Yamagata, Japan

    Takamasa Kayama

  3. Department of Neurosurgery, Saitama Medical University, Moroyama, Saitama, Japan

    Ryo Nishikawa

  4. Department of Neurosurgery, Nippon Medical University, Tokyo, Japan

    Hiroshi Takahashi

  5. Department of Neurosurgery, Osaka University School of Medicine, Osaka, Japan

    Naoya Hashimoto

  6. Department of Neurosurgery, Kyoto University School of Medicine, Kyoto, Japan

    Jun Takahashi

  7. Department of Neurosurgery, Kitano Hospital, Osaka, Japan

    Tomokazu Aoki

  8. Department of Neurosurgery, Hiroshima University School of Medicine, Hiroshima, Japan

    Kazuhiko Sugiyama

Authors
  1. Toshihiko Wakabayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takamasa Kayama
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ryo Nishikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hiroshi Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Naoya Hashimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jun Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tomokazu Aoki
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kazuhiko Sugiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Masatoshi Ogura
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Atsushi Natsume
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Jun Yoshida
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Atsushi Natsume.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wakabayashi, T., Kayama, T., Nishikawa, R. et al. A multicenter phase I trial of combination therapy with interferon-β and temozolomide for high-grade gliomas (INTEGRA study): the final report. J Neurooncol 104, 573–577 (2011). https://doi.org/10.1007/s11060-011-0529-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-011-0529-1

Keywords

Search

Navigation